EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer

Mario Campone, Michelino De Laurentiis, Komal Jhaveri, Xichun Hu, Sylvain Ladoire, Anne Patsouris, Claudio Zamagni, Jiuwei Cui, Marina Cazzaniga, Timucin Cil, Katarzyna J Jerzak, Christian Fuentes und 16 weitere

New England Journal of Medicine · 07.08.2025 · 393 (6) · 556-568

DOI: 10.1056/nejmoa2505725 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 07.08.2025. Verfasst von Mario Campone und 27 weiteren Autor:innen. Beteiligte Einrichtung: Institut de Cancérologie de l'Ouest Angers-Nantes, Saint-Herblain, France. Hauptthemen laut MEDLINE: Antineoplastic Agents, Hormonal, Breast Neoplasms, Estrogen Receptor alpha, Proteolysis Targeting Chimera. Die Arbeit wurde bisher 191-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Arvinas Estrogen Receptor, Inc., Pfizer, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Agents, HormonalBreast NeoplasmsEstrogen Receptor alphaProteolysis Targeting ChimeraEstrogen Receptor AntagonistsAdultAgedAged, 80 and overFemaleHumansMiddle AgedAdministration, OralFulvestrantKaplan-Meier EstimateMutationProgression-Free SurvivalInjections, IntramuscularTreatment OutcomeMaleBreast Neoplasms, Male

Substanzen

Antineoplastic Agents, HormonalESR1 protein, humanEstrogen Receptor alphaFulvestrantProteolysis Targeting ChimeraEstrogen Receptor Antagonists

Autor:innen und Institutionen

  • Institut de Cancérologie de l'Ouest Angers-Nantes, Saint-Herblain, France.
  • Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale," Naples, Italy.
  • Memorial Sloan Kettering Cancer Center, New York.
  • Weill Cornell Medical College, New York.
  • Shanghai Cancer Center, Fudan University, Shanghai, China.
  • Centre Georges Francois Leclerc, Dijon, France.

ORCID-Profile: Ahmet Sezer

Förderung

  • Arvinas Estrogen Receptor, Inc.
  • Pfizer, Inc.

Zitieren

APA

Campone, M., De Laurentiis, M., Jhaveri, K., Hu, X., Ladoire, S., Patsouris, A., Zamagni, C., Cui, J., Cazzaniga, M., Cil, T., Jerzak, K. J., Fuentes, C., Yoshinami, T., Rodriguez-Lescure, A., Sezer, A., Fontana, A., Guarneri, V., Molckovsky, A., Mouret-Reynier, M. A., …, & VERITAC-2 Study Group (2025). Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer. New England Journal of Medicine, 393(6), 556-568. https://doi.org/10.1056/nejmoa2505725

Vancouver

Campone M, De Laurentiis M, Jhaveri K, Hu X, Ladoire S, Patsouris A, et al. Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer. New England Journal of Medicine. 2025;393(6):556-568. doi:10.1056/nejmoa2505725

BibTeX
@article{Campone2025,
  author = {Campone, Mario and De Laurentiis, Michelino and Jhaveri, Komal and Hu, Xichun and Ladoire, Sylvain and Patsouris, Anne and Zamagni, Claudio and Cui, Jiuwei and Cazzaniga, Marina and Cil, Timucin and Jerzak, Katarzyna J and Fuentes, Christian and Yoshinami, Tetsuhiro and Rodriguez-Lescure, Alvaro and Sezer, Ahmet and Fontana, Andrea and Guarneri, Valentina and Molckovsky, Andrea and Mouret-Reynier, Marie-Ange and Demirci, Umut and Zhang, Yongqiang and Valota, Olga and Lu, Dongrui R and Martignoni, Marcella and Parameswaran, Janaki and Zhi, Xin and Hamilton, Erika P and VERITAC-2 Study Group, VERITAC-2 Study Group},
  title = {Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {393},
  number = {6},
  pages = {556--568},
  doi = {10.1056/nejmoa2505725}
}
Kostenlos starten →